Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05507164 · ClinicalTrials.gov registry record · Phase 2
Characterization of the Temporo-masseteric Nerve Block (TMNB) in Healthy Subjects
A Phase 2 study of Occlusion, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05507164 is a Phase 2 study of Occlusion that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05507164, a Phase 2 study of Occlusion, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed pilot study is aimed at preliminary characterization of the TMNB injection in 20 healthy volunteers. Assessment of bite-force distribution and surface electromyographic activity of the temporalis and the masseter muscles, at rest and clench, before and after unilateral TMNB injection, will be the primary outcome measures. Post-injection assessments will be performed at 30 minutes, 2 hours, and 2 weeks after the injection. Participants will be surveyed regarding their experience receiving the TMNB injection (secondary outcomes).
Conditions Studied
Interventions
- DRUG Temporomasseteric Nerve Block
Study Locations (1)
New Jersey
- Rutgers School of Dental Medicine - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05507164
The ClinicalTrials.gov registry entry for NCT05507164 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Occlusion appearing as the primary indexed condition, and to 1 intervention - of which Temporomasseteric Nerve Block is the first listed.
NCT05507164 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05507164 about?
NCT05507164 is a clinical study titled "Characterization of the Temporo-masseteric Nerve Block (TMNB) in Healthy Subjects". The proposed pilot study is aimed at preliminary characterization of the TMNB injection in 20 healthy volunteers. Assessment of bite-force distribution and surface electromyographic activity of the temporalis and the masseter muscles, at rest and clench, before and after unilateral TMNB injection, w...
What is the current status of trial NCT05507164?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-10-10. Estimated completion is 2026-12.
What conditions does trial NCT05507164 study?
This clinical trial studies the following conditions: Occlusion.
What interventions are being tested in trial NCT05507164?
The interventions under investigation include: Temporomasseteric Nerve Block (DRUG).
Who is sponsoring clinical trial NCT05507164?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05507164 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.